Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Boston Scientific CorporationNYSE: BSX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $1.8B rose 5.1% year over year, behind the +10.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +15.1% a year.
Context
- Selling, general & admin amounted to 34.3% of revenue in FY2025, down 1.4 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 21 analysts of $7.5B (+8.9%) for the fiscal year ending Dec 2026, a slowdown from the +15.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.8B+1.2% QoQ
- Last fiscal yearDec 2025
- $6.89B+15.1% YoY
- LTMJun 2026
- $7.16B+10.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 6.89B USD
- Year-over-year change
- +15.1%
- 4-year CAGR
- +12.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.89B | +15.1% |
| FY2024 | 2024-12-31 | 5.98B | +15.3% |
| FY2023 | 2023-12-31 | 5.19B | +14.8% |
| FY2022 | 2022-12-31 | 4.52B | +5.5% |
| FY2021 | 2021-12-31 | 4.29B | — |
Selling, General & Admin vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's LTM Jun 2026 selling, general & admin of $7.16B is the 2nd highest of the 11 companies compared; the peer median is $561.26M.
- Its year-over-year change of +10.4% is the 4th highest of 11, against a peer median of +8.8%.
- Selling, general & admin amounts to 34.1% of revenue for BSX, versus a peer median of 38.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $12.18B | +10.7% | +4.2% | 32.4% | |
| LTM Jun 2026 | $7.16B | +10.4% | +15.1% | 34.1% | |
| LTM Jun 2026 | $2.2B | +17.0% | +10.0% | 33.8% | |
| LTM Jun 2026 | $943.66M | +0.4% | -5.9% | 36.3% | |
| LTM Jun 2026 | $741.31M | +23.3% | +13.8% | 49.3% | |
| LTM Sep 2026 | $599.94M | +10.0% | +5.4% | 39.8% | |
| LTM Mar 2026 | $522.58M | +4.9% | +5.2% | 38.1% | |
| LTM Sep 2026 | $481.78M | +9.7% | +9.9% | 29.9% | |
| LTM Jun 2026 | $323.69M | +7.9% | +10.4% | 56.8% | |
| LTM Feb 2026 | $152.38M | +6.1% | +2.8% | 48.6% | |
| LTM Mar 2026 | $88.81M | +5.3% | +20.9% | 150.3% | |
| Peer median (excluding BSX) | $561.26M | +8.8% | +7.7% | 38.9% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
| Cost of Revenue | 4.43B | 4.97B | 5.41B | 6.48B | 6.22B |
| Gross Profit | 7.46B | 7.71B | 8.83B | 10.27B | 13.85B |
| Gross Margin | 62.8% | 60.8% | 62.0% | 61.3% | 69.0% |
| Research & Development | 1.2B | 1.32B | 1.41B | 1.62B | 2.05B |
| Selling, General & Admin | 4.29B | 4.52B | 5.19B | 5.98B | 6.89B |
| Operating Expenses | 5.54B | 5.89B | 6.65B | 7.63B | 9.88B |
| Depreciation & Amortization | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
| EBITDA | 2.52B | 2.74B | 3.45B | 3.94B | 5.1B |
| EBITDA Margin | 21.2% | 21.6% | 24.2% | 23.5% | 25.4% |
| Operating Income | 1.92B | 1.82B | 2.18B | 2.64B | 3.97B |
| Operating Margin | 16.2% | 14.4% | 15.3% | 15.7% | 19.8% |
| Interest Income | 4M | 10M | 22M | 107M | 0 |
| Interest Expense | 349M | 464M | 272M | 387M | 349M |
| Other Income / Expenses | (846M) | (683M) | (196M) | (353M) | (586M) |
| Income Before Tax | 1.08B | 1.14B | 1.99B | 2.28B | 3.39B |
| Pre-Tax Margin | 9.1% | 9.0% | 13.9% | 13.6% | 16.9% |
| Income Tax Expense | 36M | 443M | 393M | 436M | 493M |
| Net Income | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
| Net Margin | 8.7% | 5.5% | 11.2% | 11.1% | 14.4% |
| EPS (Basic) | 0.69 | 0.45 | 1.08 | 1.26 | 1.96 |
| EPS (Diluted) | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Weighted Avg Shares | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.